Cero Therapeutics Holdings annual r&d spending
2021
2022
2023
2024
2025
Cero Therapeutics Holdings R&D Spending Growth & History (CERO)
Cero Therapeutics Holdings's r&d spending was $10.4M for fiscal 2025.
View full Cero Therapeutics Holdings company overviewCero Therapeutics Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.4M | $4.1M | +64.39% |
| 2024 | 2024-12-31 | $6.3M | $1.0M | +19.42% |
| 2023 | 2023-12-31 | $5.3M | −$4.6M | −46.28% |
| 2022 | 2022-12-31 | $9.8M | $708,719 | +7.76% |
| 2021 | 2021-12-31 | $9.1M | — | — |
Cero Therapeutics Holdings quarterly r&d spending
Q1.23
Q2.23
Q3.23
Q4.23
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | −$1.0M | −36.96% |
| Q1 2026 | 2026-03-31 | $2.3M | −$569,482 | −19.58% |
| Q4 2025 | 2025-12-31 | $2.3M | — | — |
| Q3 2025 | 2025-09-30 | $2.4M | $612,034 | +34.50% |
| Q2 2025 | 2025-06-30 | $2.8M | $39,619 | +1.46% |
| Q1 2025 | 2025-03-31 | $2.9M | — | — |
| Q3 2024 | 2024-09-30 | $1.8M | $496,652 | +38.88% |
| Q2 2024 | 2024-06-30 | $2.7M | $1.5M | +127.51% |
| Q4 2023 | 2023-12-31 | $1.0M | — | — |
| Q3 2023 | 2023-09-30 | $1.3M | — | — |
| Q2 2023 | 2023-06-30 | $1.2M | — | — |
| Q1 2023 | 2023-03-31 | $1.8M | — | — |
Cero Therapeutics Holdings r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Cero Therapeutics Holdings's r&d spending increased from $9.1M to $10.4M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $1.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cero Therapeutics Holdings source filings ↗